TYRUKO
As listed in the register: TYRUKO
300 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Natalizumab
- Made by
- Polpharma Biologics S.a.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Polpharma Biologics S.a. |
|---|---|
| Active substance | Natalizumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 300 mg |
| Form | solution |
| Classification | L04AG03 · Cancer treatments and immune-system medicines |
| Route | intravenous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02561123 |
| DPD drug code | 106412 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.